The present invention is directed to a containment device for filling voids in bone, a process for making a containment device for filling voids in bone, and a method for use in orthopedic procedures to treat bone, and in particular to an improved device and method for reducing fractures in bone and treatment of the spine.
Medical balloons are commonly known for dilating and unblocking arteries that feed the heart (percutaneous translumenal coronary angioplasty) and for arteries other than the coronary arteries (noncoronary percutaneous translumenal angioplasty). In angioplasty, the balloon is tightly wrapped around a catheter shaft to minimize its profile, and is inserted through the skin and into the narrowed section of the artery. The balloon is inflated, typically, by saline or a radiopaque solution, which is forced into the balloon through a syringe. Conversely, for retraction, a vacuum is pulled through the balloon to collapse it.
Medical balloons also have been used for the treatment of bone fractures. One such device is disclosed in U.S. Pat. No. 5,423,850 to Berger, which teaches a method and an assembly for setting a fractured tubular bone using a balloon catheter. The balloon is inserted far away from the fracture site through an incision in the bone, and guide wires are used to transport the uninflated balloon through the medullary canal and past the fracture site for deployment. The inflated balloon is held securely in place by the positive pressure applied to the intramedullary walls of the bone. Once the balloon is deployed, the attached catheter tube is tensioned with a calibrated force measuring device. The tightening of the catheter with the fixed balloon in place aligns the fracture and compresses the proximal and distal portions of the fractured bone together. The tensioned catheter is then secured to the bone at the insertion site with a screw or similar fixating device.
As one skilled in the related art would readily appreciate, there is a continuing need for new and innovative medical balloons and balloon catheters, and in particular a need for balloon catheter equipment directed toward the treatment of diseased and damaged bones. More specifically, there exists a need for a low profile, high-pressure, puncture and tear resistant medical balloon, that can be used to restore the natural anatomy of damaged cortical bone.
The present invention relates to a device for containing material inside bone. The device may include a barrier member configured and adapted for insertion into bone, the barrier member having inner and outer surfaces, the inner surface defining a space. The barrier member may be capable of preventing fluid within the space from passing through the inner surface to the outer surface. The barrier member may comprise a polyurethane polymer based on capralactone, such that barrier member is capable of degrading into biologically compatible substances in vivo. The barrier member may include a plurality of polymer layers. Additionally, the barrier member may comprise a polyurethane polymer based on caprolactone and pluronic. The barrier member may have a tensile strength between about 15 and about 50 MPa. For example, the barrier member may have a tensile strength between about 25 and about 35 MPa. The barrier member may have a Young's modulus of between about 5 and 30. In an exemplary embodiment, the barrier member may have a Young's modulus of between about 15 and 25. The barrier member may have an elongation at break of between about 600 and 1000. For instance, the barrier member may have an elongation at break of between about 850 and 950. The barrier member may have an average molecular weight of between about 100,000 and 200,000 dalton. For instance, the barrier member may have an average molecular weight of between about 150,000 and 190,000 dalton. The mass may degrade in vivo after the device is implanted into bone or another part of the body. In an illustrative embodiment, more than about 60-percent of the mass degrades after about 16 weeks of in vivo degradation. The mass may degrade in vivo to produce carbon dioxide, water and diamine. In a non-limiting example, the barrier member may be about 0.3 mm in thickness.
The present invention is also directed to methods for treating voids in bone. One method may include accessing a cavity in bone, where the cavity has one or more boundary surfaces and may contain organic material. The cavity then may be prepared to be substantially clear from organic material. Boundary surfaces of the cavity may be spray coated with a sealant prior to filing of the cavity with a filler material. The method may further include irrigating the cavity and boundary surfaces to remove organic material and cancellous bone. Irrigating the cavity may also wash the boundary surfaces. The cavity may be aspirated to clear liquid and solid materials from the cavity and the boundary surfaces. The method may include deploying a solid barrier formed of biologically resorbable material on the boundary surfaces and placing a liquid bone filler against the barrier to fill the cavity. The method may also include preventing the transport of foreign materials from the cavity. This may involve occluding openings in the boundary surfaces and occluding voids in cancellous bone. The method may further include occluding vascular passageways in boundary surfaces of the cavity. The method may further include occluding cracks in cortical bone, where the cracks may extend into cortical bone. The method may further use an instrument to place sealant on the boundary surfaces of the cavity. The method also may include containing liquid bone filler material in the solid barrier member to form a containment device. The containment device may be filled with bone filler material. The containment device may be filled with bone filler material to substantially fill the cavity. The method may further comprise allowing the bone filler material to cure. The containment device may be implanted within the bone. Spatial relationships between the containment device and the cavity may be interpreted by fluroscopic imagery. One or more containment devices may be implanted within the bone. Enhancing the quality of fluroscopic imagery may be accomplished by assigning a distinctive radiographic signature to each containment device implanted within the bone.
Preferred features of the present invention are disclosed in the accompanying drawings, wherein similar reference characters denote similar elements throughout the several views, and wherein:
In the description that follows, any reference to either orientation or direction is intended primarily for the convenience of description and is not intended in any way to limit the scope of the present invention thereto.
The balloon 30 may be used to treat any bone with an interior cavity sufficiently large enough to receive the balloon 30. Non-limiting examples of bones that are suitable candidates for anatomical restoration using the device and method of the present invention include vertebral bodies, the medullary canals of long bones, the calcaneus and the tibial plateau. The balloon 30 can be designed and adapted to accommodate particular bone anatomies and different cavity shapes, which may be made in these and other suitably large bones.
Additionally, the balloon may be designed and configured to be deployed and remain in the bone cavity for an extended period of time. For instance, the balloon may be inflated with natural or synthetic bone filler material or other suitable inflation fluid once the balloon is located within the bone cavity. Once filled, the balloon is allowed to remain within the bone for a prescribed period or perhaps indefinitely. The duration of time that the balloon remains within the bone may depend upon specific conditions in the treated bone or the particular objective sought by the treatment. For example, the balloon may remain within the cavity for less than a day, for several days, weeks, months or years, or even may remain within the bone permanently. As explained in greater detail below, the balloon may also be adapted to serve as a prosthetic device outside of a specific bone cavity, such as between two adjacent vertebrae.
In addition, the outer surface of the balloon may be treated with a coating or texture to help the balloon become more integral with the surrounding bone matter or to facilitate acceptance the balloon by the patient. The selection of balloon materials, coatings and textures also may help prevent rejection of the balloon by the body. The inner surface of the balloon likewise may be textured or coated to improve the performance of the balloon. For instance, the inner surface of the balloon may be textured to increase adhesion between the balloon wall and the material inside.
In yet another embodiment, the balloon may be designed to rupture, tear or otherwise open after the filler material injected inside the balloon has set up or sufficiently gelled, cured or solidified. The balloon may then be removed from the bone while leaving the filler material inside. This approach may result in a more controlled deployment of bone filler material to a treated area. It also may allow the bone filler material to be at least partially preformed before being released into the bone. This may be particularly beneficial where leakage of bone filler material out of damaged cortical bone may be a concern, although there may be other situations where this configuration would also be beneficial.
Alternatively, the balloon may be opened or ruptured in a manner that would permit the filler material to allow the inflation fluid to be released into the cavity. For instance, the opening of the balloon may be predetermined so that the flow of filler material travels in a desired direction. Moreover, the filler material may be held within the balloon until it partially sets so that, upon rupture of the balloon, the higher viscosity of the filler material limits the extent to which the filler material travels.
The balloon also may be designed and configured to release inflation fluid into the cavity in a more controlled fashion. For instance, the balloon catheter might be provided with a mechanism to initiate the rupture process in a highly controlled fashion. In one embodiment, predetermined seams in the balloon might fail immediately and rupture at a certain pressure. In another embodiment, the seams might fail only after prolonged exposure to a certain pressure, temperature, or material.
One skilled in the art would appreciate any number of ways to make the balloon open or rupture without departing from the spirit and scope of the present invention. For example, at least a portion of the balloon may be dissolved until the filler material is released into the bone cavity. In another example, the balloon may rupture and become harmlessly incorporated into the inflation fluid medium. In yet another example, the filler material may be designed to congeal when contacted to a chemical treatment applied to the surface of the balloon. In yet another embodiment, two balloons (or a single balloon having two chambers) may be designed and configured to release a combination of fluids that when mixed together react to form an inert filler material within the cavity. In another embodiment, different areas of the seam or balloon might be designed to rupture at different predetermined pressures or at different times.
Further, the balloon may be designed to be opened in any number of ways. For instance, a surgeon may lyse the balloon once the desired conditions of the bone filler material are reached. A balloon adapted to rupture and release inflation fluid into direct contact with a cavity also may be designed and configured to split along predetermined seams. The seams might run parallel to the longitudinal axis of the balloon and remain secured to the catheter at the proximal tip of the balloon, resembling a banana peel which has been opened. In another embodiment, the predetermined seams might consist of a single spiraling seam originating form the distal tip of the balloon and ending at the proximal tip of the balloon, resembling an orange peel which has been opened.
Other balloon adaptations may be provided to lyse the balloon in a controlled fashion. For instance, a balloon may be constructed with failure zones that are adapted so that structural failure under a triggering condition would occur preferentially in a localized area. For instance, a balloon might have a failure zone comprising a thinner membrane. In another example, the balloon might be designed to lack tensile reinforcing elements in a particular region. In yet another example, a region of the balloon might be comprised of a material that would fail due to a chemical reaction. For instance, the chemical reaction may be an oxidation or reduction reaction wherein the material might sacrificially neutralize a weak acid or base. In another example, the sacrificial region might comprise a pattern of pore like regions. This sacrificial region may comprise a specific pattern of pores that might form a latent perforation in the balloon membrane or may be randomly distributed in a localized area.
The ruptured balloon may then be removed from the bone cavity, leaving behind the deployed bone filler material. To facilitate removal of the ruptured balloon from the bone cavity, the balloon may be treated with special coating chemicals or substances or may be textured to prevent the balloon from sticking to the filler material or cavity walls. In one embodiment, the balloon might open at the distal end. This configuration may allow the balloon to be more readily removed from the bone cavity after the balloon has opened or ruptured.
Also, biologically resorbable balloons may be designed and configured according to the present invention. For instance, a deployed balloon comprising bio-resorbable polymers might be transformed by physiological conditions into substances which are non-harmful and biologically compatible or naturally occurring in the body. These substances may remain in the patient or be expelled from the body via metabolic activity. In one example, a balloon designed to restore the anatomy of a vertebral body would be placed within a prepared cavity inside the treated vertebra and inflated with a radio-opaque filler material. Immediately after inflation (or after the filler material has partially set), the balloon may be disengaged, separated, or detached from the catheter to remain within the bone. As the balloon resorbs new bone may replace the filler material. Alternatively, the filler material may be converted by biological activity into bone or simply remain in the bone.
As one skilled in the art would readily appreciate a deployed balloon may be designed for partial or complete resorption. For instance, a selectively resorbable balloon may be configured to produce a bio-inert implant, structure, or a configuration comprising a plurality of such entities. For example, a balloon may have a resorbable membrane component and a biologically inert structural reinforcing component. In another example, a balloon designed to be selectively resorbable might form a series of bio-inert segments. These bio-inert segments might provide structural containment, or a reinforcing interface at weakened portions of the cortical bone. The segments may also be designed to cooperate and beneficially dissipate post operative stresses generated at the interface between the restored cortical bone and filler material. The precise nature of the stress reduction may be adapted to a particular anatomy.
An implanted balloon may also be designed such that it can be resorbed only after certain conditions are met. For instance, a balloon designed to provide containment in a particular region of unhealthy or damaged cortical bone may eventually be resorbed following one or more triggering conditions. In one example, the return of normal physiological conditions would trigger the break down of the balloon implant. The triggering condition may involve relative temperature, pH, alkalinity, redox potential, and osmotic pressure conditions between the balloon and surrounding bone or cancellous materials.
In another example, a controlled chemical or radiological exposure would trigger the break down of the balloon. For instance, a chemically triggered resorption may include, without limitation, a physician prescribed medicament or specially designed chemical delivered to the balloon via oral ingestion or intravenous injection. An electrical charge or current, exposure to high frequency sound, or X-rays may also be used to trigger biological resorption of the balloon.
Resorbable balloons may also provide an implanted balloon with beneficial non structural properties. For instance, soluble compounds contained within a bio-resorbable sheath may have particular clinical benefits. For example, a resorable balloon may break down when healthy cancellous bone remains in contact with the balloon for about six weeks. The breakdown of the balloon may then expose a medicament placed within the balloon structure as an internal coating. Also, the medicament may be incorporated into the balloon matrix itself to provide a time release function for delivering the medicament. The medicament may promote additional bone growth, generally, or in a particular area. Examples of other such complementary benefits include, without limitation, antibacterial effects that prevent infection and agents that promote muscle, nerve, or cartilaginous regeneration.
In use, the balloon 30 is inserted into a bone cavity that has been prepared to allow the balloon to be placed near the damaged cortical bone. Preferably, the cancellous tissue and bone marrow inside the bone and in the area to be treated may be cleared from the region in advance of deploying the balloon. Clearing the treated region may be accomplished by either shifting or relocating the cancellous bone and marrow to untreated regions inside the bone, or alternatively by removing the materials from the bone. Alternatively, cancellous bone and marrow may be cleared with a reamer, or some other device.
Additionally, the bone cavity may be irrigated and/or aspirated. Preferably, the aspiration would be sufficient to remove bone marrow within the region to be restored. In particular, a region as big as the fully deployed balloon should be aspirated in this manner. More preferably, a region exceeding the extent of the fully deployed balloon by about 2 mm to 4 mm would be aspirated in this manner. Clearing the cavity of substantially all bone marrow near or within the treated region may prove especially useful for restoring the bone and incorporating the balloon as a prosthetic device to remain in the cavity.
Clearing substantially all bone marrow from the treated area also may provide better implant synthesis with the cortical bone, and prevent uncontrolled displacement of bone marrow out of areas of damaged cortical bone. For example, a balloon for restoring a vertebral body may further comprise a prosthetic implant which will remain in the restored vertebrae for an extended period of time. Removing substantially all the bone marrow from the region of the vertebrae to be restored might provide better surface contact between the restored bone and the implant.
One skilled in the art would readily appreciate the clinical benefits for preventing the release of marrow or bone filling material to the vascular system or the spinal canal.
For example, removing substantially all the bone marrow from the treated region of the bone may reduce the potential for inadvertent and systemic damage caused by embolization of foreign materials released to the vascular system. For vertebral bodies, removing the bone marrow may also reduce the potential for damaging the spinal cord from uncontrolled displacement during deployment of the balloon or a subsequent compression of the vertebrae and implant mass.
Further, the cavity may be treated with a sealant to help prevent or reduce leakage of filler material from the cavity or to help prevent bone materials or body fluids from leaching into the cavity. Generally, sealants comprising fibrin or other suitable natural or synthetic constituents may be used for this purpose. The sealant may be applied at any suitable time or way, such as by spray application, irrigation, flushing, topical application. For example, the sealant may be spray coated inside the cavity prior to or after deployment of the balloon. In addition, the sealant may be applied to the balloon exterior as a coating so that the sealant would be delivered to the cavity as the balloon is deployed.
In another example, the sealant may be placed inside the treated area first, and then an inflatable device may be used to push the sealant outward toward the cavity walls. The inflatable device may be rotated or moved axially in order to apply the sealant. Also, the balloon may not be fully pressurized or may be gradually pressurized while the sealant is being applied.
The viscosity or other properties of the sealant may be varied according to the type of delivery and the procedure used. For example, it is preferred that the sealant is a gel if it is placed inside the cavity and the balloon is used to apply it to the cavity walls. As previously described, each of these optional steps regarding the use of a sealant may be performed after inflation of the balloon, or before, or not at all.
Thereafter, the balloon 30 is inserted into the prepared cavity, where it is inflated by fluid, (e.g., saline or a radiopaque solution) under precise pressure control. Preferably, the balloon 30 is inflated directly against the cortical bone to be restored, by an inflation device 15. In this manner, the deployed balloon presses the damaged cortical bone into a configuration that reduces fractures and restores the anatomy of the damaged cortical bone.
Following fracture reduction, the balloon is deflated by releasing the inflation pressure from the apparatus. Preferably, the balloon may be further collapsed by applying negative pressure to the balloon by using a suction syringe. The suction syringe may be the inflation device itself, or an additional syringe, or any other device suitable for deflating the balloon. After the balloon is sufficiently deflated, the balloon may be removed from the cavity, and the bone cavity may be irrigated or aspirated. Optionally, the cavity also may be treated with a sealant. The cavity then can be filled with bone filler material. The bone filler material may be natural or synthetic bone filling material or any other suitable bone cement. As previously described, each of these optional steps may be performed after inflation of the balloon, or before, or not at all.
As described more fully below, the timing of the deflation of the balloon and the filling of the cavity with bone filler material may be varied. In addition, the balloon may not be deflated prior to completing the surgical procedure. Instead, it may remain inside the bone cavity for an extended period. Thus, the method of the present invention relates to creating a cavity in cancellous bone, reducing fractures in damaged cortical bone with a medical balloon, restoring the natural anatomy of the damaged bone, and filling the restored structure of the bone with filling material.
The inflatable device may also be adapted to serve as a prosthetic device outside of a bone. One example is that the balloon may be used as an artificial disk located between two adjacent vertebrae. The use of an inflatable device in this manner may allow for replacement of the nucleus of the treated disk, or alternatively may be used for full replacement of the treated disk. Portions of the treated disk may be removed prior to deploying the inflatable device. The amount of disk material removed may depend upon the condition of the treated disk and the degree to which the treated disk will be replaced or supported by the inflatable device. The treated disk may be entirely removed, for instance, when the inflatable device serves as a complete disk replacement. If the inflatable device will serve to support or replace the nucleus or other portion of the treated disk, then less material, if any, may need to be removed prior to deployment.
The construction and shape of the inflatable device may vary according to its intended use as either a full disk replacement or a nuclear replacement. For instance, an inflatable device intended to fully replace a treated disk may have a thicker balloon membrane or have coatings or other treatments that closely replicate the anatomic structure of a natural disk. Some features include coatings or textures on the outer surface of the inflatable device that help anchor it or bond it to the vertebral endplates that interface with the artificial disk. The balloon membrane also may be configured to replicate the toughness, mechanical behavior, and anatomy of the annulus of a natural disk. The filler material likewise may be tailored to resemble the mechanical behavior of a natural disk.
In another example, if the inflatable device is intended to treat only the nucleus of the disk, the balloon may be designed with a thin wall membrane that conforms to the interior of the natural disk structures that remain intact. In addition, the balloon membrane may be resorbable so that the filler material remains after the inflatable device has been deployed. Alternatively, the balloon membrane may be designed and configured to allow the balloon to be lysed and removed from the patient during surgery. One advantage of this design would be that the balloon may function as a delivery device that allows interoperative measurement of the volume of the filler material introduced into the patient. In addition, this design allows for interoperative adjustment of the volume, so that filler material can be added or removed according to the patient's anatomy before permanent deployment. Other design features of the inflatable device and filler material described herein for other embodiments or uses also may be utilized when designing a balloon as an artificial disk.
In one embodiment of an artificial disk, the balloon is inflated with a radio-opaque material to restore the natural spacing and alignment of the vertebrae. The inflating solution or material may be cured or reacted to form a viscous liquid or deformable and elastic solid. Preferably, such a balloon may comprise an implant possessing material and mechanical properties which approximate a natural and healthy disk. For instance, the balloon may be designed for long term resistance to puncture and rupture damage, and the filler material may be designed and configured to provide pliable, elastic, or fluid like properties. Generally, filler material for a replacement disk balloon may comprise any suitable substance, including synthetic and bio-degradable polymers, hydrogels, and elastomers. For example, a balloon may be partially filled with a hydrogel that is capable of absorbing large volumes of liquid and undergoing reversible swelling. A hydrogel filled balloon may also have a porous or selectively porous containment membrane which allows fluid to move in and out of the balloon as it compressed or expanded. The filler material may also be designed and configured to form a composite structure comprising a solid mass of materials.
Balloons of the present invention also may be adapted for use as a distraction instrument and an implant for interbody fusion, such as for the lumbar or cervical regions. For instance, a inflatable device of the present invention may be used for posterior lumbar interbody fusion (PLIF). A laminotomy, for example, may be performed to expose a window to the operation site comprising a disc space. The disc and the superficial layers of adjacent cartilaginous endplates may then be removed to expose bleeding bone in preparation for receiving a pair of PLIF spacers. A balloon of the present invention may then be inserted into the disk space and inflated to distract the vertebrae. The controlled inflation of the balloon may ensure optimum distraction of the vertebrae and facilitate maximum implant height and neural foraminal decompression. Fluoroscopy and a radio-opaque balloon inflation fluid may assist in determining when a segment is fully distracted.
If the balloon is to serve as a distraction instrument, a bone or synthetic allograft along with cancellous bone graft or filler material may then be implanted into contralateral disc space. Once the implant and other materials are in the desired position, the balloon may be deflated and removed from the disk space and a second implant of the same height may be inserted into that space.
If the balloon is to serve as a spacer for intervertebral body fusion, the balloon may be inflated with a filler material that sets to form an synthetic allograft implant in vivo. Once the implant has been adequately formed, the balloon may be lysed and removed from the disk space. In another example, the inflated balloon is left intact and is separated from the catheter to remain within the disk space as a scaffold for new bone growth. As previously described, a balloon implant also may be resorbed by physiological conditions and expelled from the patient or transformed and remodeled into new bone growth.
For techniques involving multiple deployments of balloons or filler material, different radiographic signatures may be used for each deployment to enhance the quality of fluroscopic imagery and to assist the surgeon in interpreting spacial relationships within the operation site. The use of different radiographic signatures may be used, for example, with inflatable devices when they are used as instruments (such as a bone restoration tool or as a distraction device), when they are used to deliver bone filler material, or when they are used as implants. Additionally, the use of different radiographic signatures may be utilized for multiple deployment of filler material. For instance, a technique involving the deployment of two balloons between adjacent vertebrae might benefit from such an approach. Similarly, other orthopedic procedures, such as vertebroplasty, also may involve the deployment of multiple balloons having different radiographic signatures. In another example, when the balloon of the present invention is used as a PLIF spacer, the filler material within the first of two intervertebral spacer implant balloons may be provided with less radio-opacity then the second implant. As one skilled in the art would readily appreciate, varying the radio-opacity of the respective implants would facilitate fluoroscopic monitoring and deployment of the second implant. In particular, this would prevent a deployed implant on a first side from blocking the fluoroscopic image of a second implant. This advantage may also be realized when differing radiographic signatures are used in any situation involving multiple deployments, such as for multiple deployments of balloons or filler materials as described above.
The radio-opacity of each implant may be varied by incorporating different concentrations of a radio-opaque material within the filler material which inflates the balloon. For example, filler materials comprising two different concentrations of barium sulfate may be used. Similarly, different radio-opaque materials having distinguishable flouroscopic characteristics may be used.
A composite balloon comprising at least two materials that may serve as a reinforcing component and as a boundary forming component. The boundary forming component may be any suitable material used for forming a balloon. Examples of such materials are described more fully herein. The reinforcing component may provide added tensile strength to the balloon by picking up tensile stress normally applied to the boundary forming component of the balloon. The reinforcing component may be designed and configured to distribute these forces evenly about its structure, or may be designed and configured to form a space frame for the deployed balloon structure. The reinforcing component may facilitate better shape control for the balloon and provide for a thinner boundary forming component.
In one embodiment the reinforcing member component may be a braided matrix extending over selected areas of the balloon. In another embodiment, the braided matrix may enclose the balloon structure in its entirety. In another embodiment, braided matrix is on the inside of the boundary forming component of the balloon. Conversely, in another embodiment the braided matrix is located on the outside of the boundary forming component of the balloon. In one embodiment, the braided matrix is located within the boundary forming component. For example, a boundary forming component comprising a membrane might include a braided matrix within the membrane. The reinforcing strength of the braided matrix may be influenced by the type of material from which it is constructed, or by the shape and dimension of the individually braided reinforcing members.
Additionally, the reinforcing strength of the braided matrix may be determined by the tightness of the weave. For example, a more dense pattern for the braided matrix might provide greater strength but less flexability, than a less dense weave of a similar pattern. Also, different patterns may have different combinations of physical characteristics. The angle of the intersecting braided members may also be varied to optimize the physical properties of the balloon. The braided matrix may therefore be customized to provide a certain combination of physical or chemical properties. These properties may include tensile and compressive strength, puncture resistance, chemical inertness, shape control, elasticity, flexability, collapsability, and ability to maintain high levels of performance over the long term. The braided materials may be comprised of any suitable material including nitinol, polyethylene, polyurethane, nylon, natural fibers (e.g., cotton), or synthetic fibers. One firm which manufactures braided matrices of the type described above is Zynergy Core Technology.
As noted above the boundary forming component may comprise a synthetic membrane formed from polyurethane or other materials as described for the general balloon construction. The membrane may be coated on the exterior to enhance non-reactive properties between the balloon and the body, or to ensure that a balloon will not become bonded to the balloon inflation materials. Thus, a lysed balloon may be withdrawn without significant disturbance to the filled cavity. It is expected that a balloon formed from a membrane and braided matrix may designed to operate at an internal pressure of about 300 psi.
As previously described, the size and configuration of the inflation device may vary according to the particular bone to be restored.
As described in Table 1, a preferred balloon for a vertebral body would have tubing 60 with outer diameter D1 that ranges from about 1.5 mm to about 3.0 mm. The tubing 60 preferably would also be suitable for attachment to a 16 gauge catheter. As best shown in
The preferred embodiments described above include preferred sizes and shapes for balloons comprising a braided matrix and membrane. As previously noted such a balloon may be adapted to remain with a vertebral body, as a prosthetic device or implant.
Similarly, the balloon may have a combination of uniform and curved lengths comprising the tapered end of the balloon. The tapered end also may be unsymmetrical about the central axis of the balloon. A balloon comprising a braided matrix and membrane components may be of particular use in developing balloons having a tapered end or unsymmetrical geometry because the braided material can be used to improve shape control or create a space frame for the deployed balloon.
Similarly, the balloon styles depicted in
Referring to
Length L12 represents the horizontal length of the distal tapered end. Table 2 presents general preferred and preferred size ranges for this balloon configuration by target bone anatomy. Values presented in range 1 represent generally preferred dimensions and characteristics. Values presented in range 2, by comparison, represent more preferred criteria.
(a) Where L11 includes L12
As described in Table 2, the following exemplary embodiments are primarily directed toward vertebral bodies. In one embodiment, the total length L10 is about 20 mm, the working length L11 is about 15 mm, the horizontal distance L12 of the tapered distal end is about 3 mm, and the outer diameter D6 of the circular bulge is about 6 mm. In another embodiment, the balloon has similar dimensions except that the outer diameter D6 is about 8 mm. In yet another embodiment, the balloon diameter D6 is about 12 mm.
As described in Table 3, the following exemplary embodiment is primarily directed toward vertebral bodies. In one embodiment, the total length L13 is about 20 mm, the working length L14 is about 15 mm, and the horizontal distance L15 of the tapered distal end is about 3 mm. Further, the vertical height L16 and the lateral width L17 of the balloon 145 are 14 mm and 14 mm, respectively.
Referring to
Additionally, in other general embodiments of complex balloons as depicted in
In yet another exemplary embodiment of a complex balloon,
In addition, length L25 and length L26 of the U-rod 185 preferably extend beyond the distal edge 200 of the balloon deployment opening 170 to provide a suitable anchoring length L27 for the U-rod 185 within the catheter 165. U-rod segment lengths L25 and L26 need not be equal. The rounded tip 205 of the U-rod 185 may be fully recessed or may partially extend from the proximal end 175 of the catheter 165. In one embodiment, the tip 205 of the U-rod 185 is secured to the catheter 165 by a soldered, brazed or welded connection. A glued fastener or other attachment means may also be used. For instance, a snap together fastening method may be used. Depending on the number of balloon deployment openings 170 and the material of catheter 165 construction, the number of reinforcing rods 185 will vary. Also, the means for joining a plurality of reinforcing rods 185 together and connecting the reinforcing rods 185 to the catheter 165 may vary from the embodiments shown.
In addition, multiple rods may be used instead of a U-rod to accommodate a reinforced catheter with a plurality of balloon deployment openings. One skilled in the art would readily appreciate that one particular geometry of reinforcing rods may prove easiest to manufacture, assemble, or configure. Therefore, one embodiment may prove to be the most cost effective solution for a particular balloon configuration. For this reason, these embodiments are not intended to be a complete set of cross sections contemplated by the invention, rather general illustrations of the reinforcing rod concept. TABLE 4 presents general dimensions for the catheter depicted in
(a) Outer Diameter
(b) Inner Diameter
Reinforcing elements, alternatively, may be individual rails which are connected to and oriented around the catheter perimeter by a plurality of spacer rings which are mounted on an internal lumen. The reinforcing elements may further be wire elements that are post tensioned at the distal tip of the catheter. For this reason, the relative sizing of the balloon deployment window, the catheter strips and the reinforcing elements may be reconfigured to accommodate a particular anatomical, mechanical, therapeutic, or clinical need.
For example,
In yet another embodiment, shown in
As shown further in
One skilled in the art would readily appreciate that more apertures may be used as appropriate to effect the desired rate of fluid transfer, and that a folded multi-chamber balloon may be simple to assemble and test during manufacturing. Thus, creating complex balloons from a folded multi-chamber balloon 250 embodiments may also provide cost savings.
Similarly,
Non-limiting examples of specially formulated biodegradable polyurethanes are disclosed in the following exemplary published materials, the contents of which is fully incorporated herein by reference: (1) Goma, K., and Gogolewski, S., “In vitro degradation of novel medical biodegradable aliphatic polyurethanes based on e-caprolactone and Pluronics® with various hydrophilicities,” Polymer Degradation and Stability 75 (2002), pp. 113-122; and (2) Gorna, K., and Gogolewski, S., “Novel Biodegradable Polyurethanes for Medical Applications,” Synthetic Bioabsorbable Polymers for Implants, ASTM STP 1396, C. M. Agrawal, J. E. Parr, and S. T. Lin, Eds. American Society for Testing and Materials, West Conshohocken, Pa., 2000.
Nevertheless, the balloon or containment device need not comprise a resorbable material. For example, the containment device may comprise an inherently rigid polyester material that is prepared as a sufficiently thin barrier so as to have the desired flexibility and strength for use as a balloon or containment device. Such a barrier may be formed with or without conventional plasticizers known in the related art.
The containment device may have one or more openings 442 for receiving filler material. The containment device may be used to contain and capture various bone void fillers, such as bone cement, calcium phosphate cement, bone chips, and demineralized bone, within a bone void. The containment device 440 is inserted into a void in the bone, and the containment device is then backfilled with a bone void filler. The bone void filler material may expand the containment device into the available space or the containment device may be placed against the bone void surfaces in a partially or fully expanded position and then filled with bone void filler. The device contains the filler material, preventing extravasation (extraosseous flow) of the filler material into surrounding tissues, and then degrades in vivo. The containment device may be used, for example, in filling bone voids in the vertebral bodies of the spine, as well as in long bones and the craniomaxillofacial skeleton.
Resorbable portions of the containment device may be formed from polymer films made from synthetic materials, naturally occurring materials, modified naturally occurring materials and combinations thereof. For instance, materials suitable for synthesizing polymer films for the containment device may be formed wholly or in part from biodegradable polyurethane based on ε-caprolactone (e.g., polycaprolactone-based elastomers), which can be transformed into a film by solution casting (e.g., dip coating). The device also may be formed from a melt. Another suitable polyurethane is based on polycaprolactone-polyethylene oxide-polypropylene oxide-polyethylene oxide (Pluronic). The Pluronic may be dissolved, for example, in tetrahydrofuran.
Resorbable materials for preparing the containment device may also include polymers such as highly purified polyhydroxyacids, polyamines, polyaminoacids, copolymers of amino acids and glutamic acid, polyorthoesters, polyanhydrides, polyamides, polydioxanone, polydioxanediones, polyesteramides, polymalic acid, polyesters of diols and oxalic and/or succinic acids, polycaprolactone, copolyoxalates, polycarbonates or poly(glutamic-co-leucine). Preferably used polyhydroxyacids may comprise polycaprolactone, poly(L-lactide), poly(D-lactide), poly(L/D-lactide), poly(L/DL-lactide) polyglycolide, copolymers of lactide and glycolide of various compositions, copolymers of said lactides and/or glycolide with other polyesters, copolymers of glycolide and trimethylene carbonate, poly(glycolide-co-trimethylene carbonate), polyhydroxybutyrate, polyhydroxyvalerate, copolymers of hydroxybutyrate and hydroxyvalerate of various compositions. Other materials which may be used as additives are composite systems containing resorbable polymeric matrix and resorbable glasses and ceramics based e.g. on tricalcium phosphate and/or hydroxyapatite, admixed to the polymer before processing.
Polymer films for forming a containment device, preferably, may be specially designed to exhibit one or more desired properties. Specifically, polymer films may be formulated to have specific mechanical and chemical properties. For instance, polymer films may be designed to have a low Young's modulus; a high tensile strength; a fast resorption rate; and a high elongation at break.
Polymer films may be formulated for different degradation rates in vivo. A polymer film may be designed to substantially degrade in a matter months, weeks, or days. In an illustrative embodiment, a polyurethane film made from a polyurethane polymer may be designed to have a thickness of about 0.3 mm and may be designed to substantially degrade in vivo within one-year after implantation. In another embodiment, the polyurethane film may be designed to substantially degrade in vivo within 16 weeks after implantation. Thus, the rate of resorption and the loss of mechanical properties of the containment device in vivo may be adapted to allow maintenance of its functionality during a post-operative healing period. The rate of resorption, preferably may be controlled taking into account that such factors as polymer weight, crystallinity, polymer chain orientation, material purity, the presence of copolymer unit in the chain. The presence of voids (porosity) will affect the rate of resorption. In general the rate of resorption increases in the presence of a material with voids, pores, impurities, copolymer units. The rate of degradation decreases with the increase of polymer molecular weight, crystallinity and chain orientation.
Preferably, a suitable polymeric material may have a degradation rate in vivo in the range of 6 weeks to 24 months. Viscosity-average molecular weight of polymers to be suitable for preparation of the containment may be in the range of 30,000 to 900,000 and preferably 180,000 for elastic or semi-elastic of the containment device, and preferably 300,000 to 400,000 for harder implants.
The clinical need may also effect the formulation of the polymer and properties of the containment device. For example, a balloon or containment device which is to be implanted within a more heavily damaged bone may require a containment device that is designed to degrade more slowly in order to provide additional structural integrity to the implant or some other therapeutic benefit. A polyurethane based containment device, therefore, may include therapeutic materials which are beneficially released during the degradation of the device as part of a pre-determined and longer term therapy. For instance, the containment device may be designed to degrade substantially over a target period of several months. In an application for filling voids in bone, where it may be a primary objective to prevent the extraosseous flow of bone filler material, the biodegradable polymer may preferably have a have a low Young's modulus, a high tensile strength, fast resorption and high elongation. The rate of degradation of the film may be then be formulated to meet such a clinical need. Moreover, the polymer film may degrade in vivo to produce end products that are bio-compatible and that do not adversely affect the bone filler which has been placed inside the balloon or containment device. For example, the degradation products of a suitable urethane polymer device may include carbon dioxide, water, and diamine.
Resorbable or degradable polymeric and/or polymeric-ceramic materials for forming containment devices may have a Young's modulus in the range of 1 to 100 MPa and a tensile strength in the range of 1 to 100 MPa. The Young's modulus should preferably be in the range of 5 to 50 MPa, most preferably in the range of 15 to 25 MPa. The tensile strength should preferably be in the range of 15 to 50 MPa, most preferably in the range of 25 to 35 MPa. For example, the containment device may be formed from polyurethane materials synthesized from mixtures of polyethylene oxide with caprolactone or mixtures of polycaprolactone with triblock copolymers of ethylene oxide-propylene oxide-ethylene oxide. These materials may have an initial tensile strength in the range of 35 to 47 MPa, a moduli in the range of 22 to 31 MPa, and elongation at break in the range of 800% to 900%. Such materials may undergo rapid degradation. One embodiment of a polyurethane containment device formed from caprolactone and Pluronic (PEO-PPO-PEO) may loose about 65% of its mass after about 16 weeks of in vivo degradation.
Table 5 summarizes representative values for the physical characteristics of several foils prepared from pluronic solutions (i.e., polycaprolactone-polyethylene oxide-polypropolyne oxide). Each foil comprised an area of about 150 mm×150 mm and had a thickness of about 0.3 mm.
Notes:
(a) Pluronic (polycaprolactone-polyethylene, oxide-polypropylene, and oxide-polyethylene oxide);
(b) Polycaprolactone, and polyethylene oxide
(c) e-caprolactone.
Table 6 by contrast summarizes the preferred physical properties for a pluronic based resorbable containment device for low pressure applications. In this application, the containment device may be designed to prevent extravasation when a void in bone is filled with a filler material like bone cement.
Resorbable containment devices may be made by solution casting successive layers of polymer film onto a mandrel or mold. For example, a polyurethane polymer based on Pluronic having a viscosity-average molecular weight of 104.000 dalton may be used to prepare the polymer film. In another example, a pluronic-based polyurethane may be dissolved in tertahydofuran to prepare a 2.5 wt/vol-% solution. Other pluronic-based polymer materials having a different viscosity-average molecular weight and/or polymer concentration may also be used to prepare the polymer film for the containment device. Pluronic-based materials having a viscosity-average molecular weight of 180.000 dalton and a polymer concentration of 3%, 4%, or 5% may also be prepared. The concentration of the copolymer unit in the polymer may be in the range of about 1 to about 99% and preferably in the range of about 2.5 to about 35%. The polymeric material may have at least a partially oriented structure.
Referring to
Referring to
Referring back to
Referring to
A resorbable containment device 440 may then be solution cast on the mold 450 and strand 480. The strand 480 may also be placed over a partially or completely cast containment device. Additional solution casting of resorbable polymer may then be applied to partially or completely cover the strand. Thus, a resorbable containment device 440 may be formed with a strand 480 located within the wall 445 of the resorbable containment device, on the inside surface of the containment device, or on the outside surface 470 of the containment device.
Resorbable containment devices may also be made from individually cast molds. Individually formed sections of resorbable polymer may be applied directly to bone or may be combined to create barriers or larger containment structures. For instance, individual pieces of a composite containment device may be joined and/or sealed together for low pressure filling with bone cement in vivo, by drip coating the joints between the individual pieces of the composite device with pluronic based solution. Alternatively, any suitable adhesive may be used to join pieces into a unitary structure. Individual sections of resorbable polymer may also be stitched together with suture material. The stitching may be designed to provide a leak free structure or may require additional sealing of the seams. Automated spray coating of molds formed by CAD/CAM and other known processes may be used to form containment devices of a wide variety of shapes, sizes and materials. Resorbable containment devices may also be produced using standard techniques of polymer processing, mainly by injection-molding, compression-molding and in-mold polymerization.
While the above invention has been described with reference to certain preferred embodiments, it should be kept in mind that the scope of the present invention is not limited to these embodiments. For example, the containment device may be formed with a strand that extends from the resorbable polymer to form a free end. The free end may be used to secure the containment device or tie off the opening. The embodiments above can also be modified so that some features of one embodiment are used with the features of another embodiment. One skilled in the art may find variations of these preferred embodiments which, nevertheless, fall within the spirit of the present invention, whose scope is defined by the claims set forth below.
This is a continuation-in-part of pending U.S. patent application Ser. No. 10/636,549, filed Aug. 8, 2003, which further claims the benefit under 35 U.S.C. § 120 of U.S. patent application Ser. No. 09/908,899, filed Jul. 20, 2001, now U.S. Pat. No. 6,632,235 B2, which claims the benefit under 35 U.S.C. § 119(e) of Provisional Application No. 60/284,510, filed Apr. 19, 2001. All the foregoing documents are herein incorporated by reference.
Number | Date | Country | |
---|---|---|---|
60284510 | Apr 2001 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09908899 | Jul 2001 | US |
Child | 10636549 | Aug 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10636549 | Aug 2003 | US |
Child | 11067438 | Feb 2005 | US |